Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Expert Urges Companies to Heed Whistleblowers

This article was originally published in The Gray Sheet

Executive Summary

As device makers come under more scrutiny for fraud from the federal government, David Marshall, an attorney who specializes in whistleblower cases, says companies that deal with non-compliance issues early are much more likely to get lenient treatment than those who try covering them up.

You may also be interested in...



Stryker's OtisMed Pleads Guilty For Selling FDA-Rejected Cutting Guides

The unit and its former CEO admitted to selling knee-replacement instruments even after FDA rejected a 510(k), prior to OtisMed being acquired by Stryker in 2009. The legal resolution comes with about $80 million in fines and possible jail time for the former CEO. Also, Stryker has agreed to conduct an audit on the FDA approval status of devices in its portfolio.

Medtronic Settles False Claims Case For $9.9 Million

The company has resolved allegations from the Department of Justice to that it paid illegal kickbacks to doctors to implant Medtronic pacemakers and defibrillators.

News Briefs: Boston Sci Settlement; C.R. Bard Scores Patent Victory

Boston Scientific owes another $30 million to settle more charges related to Guidant ICD issues. C.R. Bard closer to receiving big payout from Gore on patent case. FDA issues a safety alert on St. Jude’s Amplatzer occluder More news briefs.

Topics

Related Companies

UsernamePublicRestriction

Register

LL035386

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel